Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTreat: Palonosetron for OINV Prophylaxis in Palliative Cancer
NCT05315999Phase 2Completed
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palonosetron in Opioid-induced nausea and vomiting (OINV). Primary endpoints: Feasibility of the study design at 12 months and Number of patients who show no relevant increase of nausea. Started May 2022; status: completed.
02
Drugs
palonosetron
03
Conditions
Opioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on NCT05315999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315999.